Main Therapeutic Uses

Ivor 3500 U.I. contains bemiparin sodium, a low molecular weight heparin (LMWH). This medication is primarily utilized to prevent the formation of blood clots in the veins, a condition known as venous thromboembolism.

Prevention of Venous Thromboembolism

The primary application of this treatment is the prevention of blood clots in specific clinical scenarios where the risk of clot formation is elevated:

• General Surgery: It is used to reduce the risk of venous clots in patients undergoing general surgical procedures.
• Orthopedic Surgery: It is indicated for patients undergoing major orthopedic operations, such as hip or knee replacements, where the risk of deep vein thrombosis is significantly higher.
• Non-Surgical Medical Patients: It may be used in acutely ill medical patients who have reduced mobility and are considered at high risk for thromboembolic complications.

Secondary Prevention

In addition to primary prevention, this medication is used to prevent the recurrence of venous thromboembolism in patients who have already experienced a clot and are undergoing surgical procedures.

Benefits and Mechanism of Action

The benefit of Ivor 3500 U.I. lies in its ability to modify the body's natural blood-clotting process. By inhibiting specific proteins in the coagulation cascade, such as Factor Xa, the medication helps maintain blood flow and prevents the development of thrombi (clots) that could potentially travel to the lungs or other vital organs.

Therapeutic Advantages

• Predictable Response: As a low molecular weight heparin, it offers a consistent pharmacological effect.
• Targeted Action: It focuses on specific stages of the clotting process to provide effective prophylaxis while minimizing impact on overall primary hemostasis.
• Support for Recovery: By mitigating the risk of clot-related complications, it supports the stabilization of patients during the post-operative recovery period or during bouts of acute illness.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Ivor 3500 U.I. (bemiparin sodium) is intended for use in the adult population who do not have specific exclusionary conditions. Regulatory authorities define strict eligibility based on a patient’s medical profile and physiological status.

Absolute Contraindications

The medicine must not be used if a patient has active hemorrhage, a confirmed or suspected history of Heparin-Induced Thrombocytopenia (HIT), or known hypersensitivity to the drug. Use is also strictly contraindicated in patients with severe liver and pancreas impairment or those who have had recent surgery or trauma to the central nervous system, eyes, or ears.

Restricted and Conditional Use

Use of Ivor 3500 U.I. is not recommended in the pediatric population (children and adolescents), pregnant women, or breastfeeding women, as safety and efficacy have not been clinically established in these groups. For patients with severe renal impairment, use may be permitted but requires careful clinical monitoring and possible dose adjustment. Caution is also advised in patients with uncontrolled arterial hypertension or a history of gastro-duodenal ulcers.

Interactions with other medicines and products

Ivor 3500 U.I. (bemiparin sodium) interactions with other medicinal products are documented primarily through pharmacodynamic reinforcement and specific administration constraints, as formal pharmacokinetic interaction studies have not been conducted.

Documented Interaction Patterns

Interactions Increasing Bleeding Risk The concomitant use of Ivor 3500 U.I. with certain medicines is officially classified as not advisable due to the enhanced risk of bleeding. These medicines interfere with the body's coagulation and/or platelet function, leading to an additive effect. This category includes Vitamin K antagonists, other anticoagulants, salicylates and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), platelet inhibitors (such as ticlopidine and clopidogrel), systemic glucocorticoids, and dextran.

Interactions Affecting Electrolyte Levels Bemiparin, like other Low Molecular Weight Heparins, can lead to a risk of hyperkalaemia (elevated plasma potassium) by suppressing adrenal aldosterone secretion. This risk is amplified when co-administered with potassium-sparing drugs, especially in individuals with conditions such as chronic renal failure, diabetes mellitus, or pre-existing metabolic acidosis.

Administration Constraints To avoid the potential for local hematoma formation during treatment, the intramuscular injection of any other medicinal agent must be avoided.

How Ivor 3500 U.I. Works

Ivor 3500 U.I. influences a critical step in the blood coagulation cascade through a selective, enzyme-mediated interaction. The drug functions by binding to and markedly increasing the inhibitory potency of the naturally occurring anticoagulant protein, Antithrombin III (ATIII). This potentiation of ATIII's activity leads to the rapid and specific neutralization of activated Factor Xa (FXa), a key enzyme essential for propagating the clotting process.

The inactivation of Factor Xa directly suppresses the enzyme responsible for converting prothrombin into active thrombin (Factor IIa). This interruption reduces the burst of thrombin generation, which impairs the final polymerization of fibrinogen into the insoluble fibrin mesh. The resulting physiological effect is a reduced rate of coagulation, establishing an overall change in hemostatic balance.

Method of Administration

Ivor 3500 U.I. is typically administered via subcutaneous injection. This involves the use of a pre-filled syringe designed for single-use application. The injection is generally directed into the fatty tissue layer just beneath the skin, commonly in the abdominal area, avoiding the immediate vicinity of the navel.

Preparation for Use

Before administration, the injection site should be clean. The pre-filled syringe is prepared by removing the needle cap. It is standard practice to avoid purging the air bubble from the syringe prior to injection to prevent the loss of medication and to minimize local bruising at the site of entry.

Injection Technique

The procedure involves grasping a fold of skin between the thumb and forefinger to create a stable area for the needle. The needle is inserted vertically—at a 90-degree angle—into the skin fold. The plunger is depressed steadily until the entire volume of the syringe has been delivered. Once the injection is complete, the needle is withdrawn, and the skin fold is released.

Site Rotation and Post-Injection Care

To maintain skin integrity and ensure consistent absorption, the site of injection should be rotated between the left and right sides of the body for subsequent applications. It is recommended not to rub the injection site after the procedure, as this can increase the risk of localized irritation or hematoma formation.

Disposal

After use, the syringe and needle must be disposed of in a designated puncture-resistant container. These items are for single use only and should not be reused or shared.

Research Evidence / Overview of Studies

---

Early Clinical Trials

Research has explored whether the combination of Drug X and Compound Y is being explored for potential future use in studying conditions such as osteoarthritis and chronic lower back discomfort. This early-stage research focused primarily on safety, dosage, and tolerability in human subjects.

• Initial Phase I and II trials centered on examining whether the combination might be associated with improvements in both discomfort and movement capacity in individuals with moderate knee osteoarthritis.
• One key study reported observations suggesting that changes in dosage were associated with changes in discomfort and function.

---

Scope of Studies

Studies have been conducted to explore use across a wide range of painful musculoskeletal and inflammatory conditions.

• The majority of trials involve participants experiencing localized pain in major joints (knees, hips, shoulders).
• Research has not yet concluded on suitability for treating systemic autoimmune disorders.

---

Actions Studied in Research

Research is investigating the actions of Drug X and how they relate to changes in discomfort. Compound Y is included in studies to assess potential associations with the duration of Drug X's presence in the body.

• This approach was studied for its association with prolonged decreases in discomfort and findings related to safety were evaluated.

---

Patient Suitability Notes

Data reviewed in research indicates that suitability is highly individual and depends on numerous patient-specific factors (e.g., condition severity, co-morbidities, other medication use).

Key Studies & References

1. Phase 2b Randomized Controlled Trial of Drug X/Compound Y Combination in Moderate Knee Osteoarthritis: Safety and Efficacy Metrics
2. Guideline for the Management of Chronic Musculoskeletal Pain in Adults

Common questions about Ivor 3500 U.I. (FAQ)

Q: Is Ivor 3500 U.I. the same as other medicines for the same condition?

Ivor 3500 U.I. (bemiparin sodium) belongs to the category of blood thinners known as Ultra-Low Molecular Weight Heparins (Ultra-LMWH). Official documents note that it has a distinctive profile, including a lower molecular weight and a specific ratio of anti-clotting activities (anti-Xa to anti-IIa), which contributes to its specific activity profile relative to other anticoagulant medicines.

Q: How quickly should Ivor 3500 U.I. start to work after I begin taking it?

Regulatory data on the drug's absorption indicates that the maximum anti-clotting effect, measured by the level of Factor Xa inhibition in the blood, is typically reached approximately 2 to 3 hours after a subcutaneous injection. This measurement reflects the time of peak anti-clotting activity.

Q: Is Ivor 3500 U.I. generally safe for older adults (seniors)?

The official product information indicates the drug is intended for use in the adult population. No general age-related dose adjustments or specific contraindications based solely on advanced age are listed. Suitability for use is based on an individual's overall medical profile and co-existing conditions, such as kidney function.

Q: What is the longest period of time people typically use Ivor 3500 U.I.?

For prevention of blood clots (prophylaxis) after surgery, regulatory documents commonly recommend use for at least 7 to 10 days. In specific situations, such as the management of established blood clots, use for up to several months may be documented. The duration of use is determined based on the individual's clinical needs and risk assessment.

Q: Does taking Ivor 3500 U.I. affect blood pressure readings?

Official safety notes advise caution when using the drug in patients with uncontrolled arterial hypertension (high blood pressure). The drug may also increase the risk of hyperkalaemia (elevated potassium levels), which can impact heart rhythm. However, official warnings do not state that the drug typically changes blood pressure readings in the absence of other risk factors.

Q: Is Ivor 3500 U.I. safe for women who are pregnant or planning to be?

Official documents state that the drug's use is not recommended during pregnancy or for women who are breastfeeding. This is because the safety and efficacy of the drug have not been fully established in these specific populations.

Q: Do studies support the long-term effectiveness of Ivor 3500 U.I. ?

Research has been conducted to investigate the profile of Ivor 3500 U.I. when used for an extended duration, such as in the management of established blood clots. These studies provided information regarding the drug's profile when used over several months.

Q: Are there different forms of Ivor 3500 U.I., like tablets vs. capsules?

Official product information specifies that Ivor 3500 U.I. is exclusively supplied as a sterile solution for injection contained within a pre-filled syringe for subcutaneous use. No tablet, capsule, or other oral forms of this medication are currently listed in regulatory documents.

Q: Can Ivor 3500 U.I. affect mood or cause anxiety?

Adverse reaction listings in official regulatory documents, which categorize known side effects, do not include psychiatric disorders, anxiety, or specific mood changes as documented effects of this medication.

Q: How long does Ivor 3500 U.I. stay in the body after the last use?

The drug's anti-clotting activity is associated with an approximate elimination half-life of 5 to 6 hours. This indicates the approximate time required for the body to eliminate half of the drug's anti-clotting activity.

Q: What kind of research has been conducted on Ivor 3500 U.I. in children?

The drug's use is not recommended in the pediatric population (children and adolescents). This is because comprehensive data on safety and efficacy in children is limited or not available.

Q: Can Ivor 3500 U.I. cause problems with sleep or insomnia?

Sleep disturbances, such as insomnia, are not listed among the officially categorized or commonly reported adverse reactions in the regulatory safety profile for this drug.

Q: Does Ivor 3500 U.I. need to be taken with food, as a general rule?

Since Ivor 3500 U.I. is administered as a subcutaneous injection (under the skin), its delivery is independent of the digestive process. Official administration instructions do not require the injection to be timed around food intake.

Q: Are there any special considerations for people with diabetes using Ivor 3500 U.I. ?

Official safety documents identify individuals with diabetes mellitus as a group that may have an increased risk of developing hyperkalaemia (elevated plasma potassium levels) while using this medication, especially if treatment is prolonged beyond seven days.

Q: Is hair loss listed as a potential side effect of Ivor 3500 U.I. ?

Hair loss (Alopecia) is not listed among the officially categorized or commonly reported side effects in the comprehensive regulatory documents for this medication.

Q: Can using Ivor 3500 U.I. cause sensitivity to sunlight?

Photosensitivity, or an increased sensitivity to sunlight that results in skin reactions, is not listed among the officially documented adverse reactions in the regulatory safety profile.

Q: Can people with lactose intolerance safely use Ivor 3500 U.I.?

Official product information lists the composition of the injection solution. Given its composition as a liquid injection, it is not expected to contain lactose or related sugars often found in oral dosage forms.

Q: How does the '3500 U.I.' part of the name relate to its strength?

The numerical part, 3500 U.I. (International Units), represents the strength of the drug's anti-clotting action. It is a specific measurement of its ability to inhibit a key clotting substance called Factor Xa, which is formally termed its anti-Xa activity.

Q: Is Ivor 3500 U.I. an antibiotic or an anti-inflammatory drug?

Ivor 3500 U.I. is classified by regulatory authorities as an anticoagulant (a blood thinner) belonging to the Heparin family. Its primary function is to prevent blood clot formation, and it is not classified as an antibiotic or an anti-inflammatory drug.

Q: Can Ivor 3500 U.I. be taken by people with a history of heart issues?

Safety documents advise caution for patients with a history of uncontrolled arterial hypertension and note a risk of hyperkalaemia (high potassium), which can affect heart function. Use is otherwise generally permitted in adults unless a specific cardiac condition is listed as an absolute contraindication.

Q: Is it possible for Ivor 3500 U.I. to lose its strength before the expiration date?

Regulatory requirements mandate strict storage conditions, such as storing below 25 C and keeping the product protected from light and freezing. These strict conditions are required to maintain the drug's strength and stability until the specified expiration date.

Q: Is a metallic taste in the mouth a known side effect of Ivor 3500 U.I.?

A metallic taste in the mouth is not listed among the formally classified side effects documented in the official regulatory safety profile for this medication.

How to Store and Dispose of Ivor 3500 U.I.

Official Storage Requirements

Ivor 3500 U.I. (bemiparin sodium) must be stored in strict compliance with the conditions detailed in the official regulatory labeling.

Condition	Requirement
Temperature	Store below 25 C (not to exceed 77°F).
Freezing	Do not freeze the product.
Protection	Keep in the original container (blister pack) to protect the solution from light and moisture.

Handling and Disposal Rules

This medication must be kept out of the sight and reach of children to ensure safety. The pre-filled syringe should remain in its packaging until immediate use. When the product is expired or unused, disposal must be done responsibly: it must not be thrown away via household waste or wastewater. All unused medicine must be returned to a pharmacist for safe handling as pharmaceutical waste.